Ocular Therapeutix closes eye treatment study enrollment ahead of PMA bid

Wed, 09/05/2012 - 1:50pm
Mass Device

Ocular Therapeutic closes enrollment on a pivotal trail of its ReSure hydrogel sealant, the findings from which will support the company's bid for FDA pre-market approval.

Ocular Therapeutix logo

Ocular Therapeutix completed enrollment in a pivotal trail of its ReSure sealant, a hydrogel used to protect ocular incisions following eye surgery.

Findings from the 488-patient study will support the company's bid for pre-market approval for ReSure, aiming for the agency's approval to market the device in treating post-operative corneal wounds.

Applied as a liquid, the product gels to form a barrier on the surface of the eye following cataract surgery, the most common eye surgery performed in the U.S., according to a press release.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.